生命科学资讯

Aktis Oncology aims for $209M windfall from 1st biotech IPO of 2026

Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit

Abbott launches AI-based Libre Assist, its new in-app feature for meal planning

MetaVia weighs in with 9% loss as dual agonist enters the obesity ring

2025 by the numbers: Layoff rounds rise 16% YOY

Cash-strapped TME Pharma loses partner, prompting eye drug strategy rethink

Teverelix: A New Direction in Prostate Cancer and Urologic Health

Insilico, fresh off its Hong Kong IPO, pens potential $888M cancer R&D pact with Servier

Fierce Biotech Layoff Tracker 2026: Nido winds down

Cellular energy booster restores cognition in mice with advanced Alzheimer’s disease

NIH instability grows with exit of neuro director, leaving half of institutes under interim leadership

Sanofi, Corcept surprised by FDA rejections for MS, Cushing's syndrome drugs

Neuralink to kick-start 'high-volume production' of brain-computer interface devices, Elon Musk says

J&J junks $1.2B eczema therapy while Genmab clears out cancer drug

Neuro biotech Nido closes after phase 2 study fails to move needle in rare disease

AbbVie, Gilead gift themselves clinical-stage cancer drugs via licensing deals

Biohaven flunks phase 2 depression trial, adding to concerns for pivotal epilepsy readout

Ultragenyx plans major cost-cutting push after flunking phase 3 brittle bone trials

Quanterix's blood test for Alzheimer's disease uncovers potentially treatable population in decades-long study

Breast cancer tops list of most-studied diseases for 5th year in a row: report